Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

End-of-day quote. End-of-day quote  - 02/12
70.9 CHF   +1.94%
02/12 NOVARTIS : Sandoz Acquires Rights of Biosimilar Infliximab from Pfiz..
02/12 NOVARTIS : Sandoz acquires rights to biosimilar infliximab in the EE..
02/12 NOVARTIS : Sandoz strengthens its biosimilars portfolio with acquisi..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
02/08/2016 02/09/2016 02/10/2016 02/11/2016 02/12/2016 Date
71.75(c) 70.4(c) 71.9(c) 69.55(c) 70.9(c) Last
7 931 396 11 051 565 10 240 125 10 667 609 6 271 323 Volume
-2.91% -1.88% +2.13% -3.27% +1.94% Change
More quotes
Financials ($)
Sales 2016 49 495 M
EBIT 2016 12 353 M
Net income 2016 9 127 M
Debt 2016 10 773 M
Yield 2016 3,93%
Sales 2017 51 613 M
EBIT 2017 13 794 M
Net income 2017 10 434 M
Debt 2017 7 119 M
Yield 2017 4,21%
P/E ratio 2016 19,85
P/E ratio 2017 17,39
EV / Sales 2016 4,16x
EV / Sales 2017 3,92x
Capitalization 195 106 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines & Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical,... 
Sector
Pharmaceuticals
Calendar
02/11 | 03:30pmPresentation
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
02/12 NOVARTIS : Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer
02/12 NOVARTIS : Sandoz acquires rights to biosimilar infliximab in the EEA
02/12 NOVARTIS : Sandoz strengthens its biosimilars portfolio with acquisition of Pfiz..
02/11 NOVARTIS : Sandoz advances its biosimilars program with EMA acceptance of regula..
02/10 NOVARTIS : Fixtures
02/10 NOVARTIS : Microsoft and Novartis fight Multiple Sclerosis with Kinect
02/10 NOVARTIS : From gaming system to medical breakthrough: How Microsoft and Novarti..
02/10 NOVARTIS : Enters into Agreement with Microsoft
More news
Sector news : Pharmaceuticals - NEC
02/12 AMGEN : Mystery cannabis 'consortium' reportedly interested in Longmont's Amgen ..
02/12DJSHIRE : Files 8K - Other Events
02/12DJLILLY : U.K. Court Rules in Opponent's Favor on Alimta Patent
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/11 Tracking Tweedy Browne Portfolio - Q4 2015 Update
02/10 MASSACHUSETTS-BASED PROTEOSTATIS THE : Early Stage And Stiff Competition Keeps U..
02/10 MEDTECH SERIES : Why Medical Technology Companies Should Have A Place In Your Po..
02/10 Novartis agrees to performance-based pricing with key insurers for heart fail..
02/09 These O'Shares ETFs Focus On Quality European Dividends


Comments 
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions